肝内胆管细胞癌诊治进展

doi:10.3969/j.issn.1000-8535.2023.06.018

摘要/Abstract

摘要： 肝内胆管细胞癌（ICC）是发病率仅次于肝细胞癌的肝脏恶性肿瘤,它的恶性程度高、术后易复发,且早期无典型症状,大多数患者在确诊时已处于晚期。诊断主要依赖于增强CT、MRI和实验室检查。肝切除术是ICC首选的治疗方法,完整的切缘阴性切除和保留足够残留肝是影响手术预后的重要因素。淋巴结清扫、卡培他滨辅助化疗已被证实对患者有益。局部治疗、分子靶向治疗、免疫治疗等新疗法发展迅速,为晚期ICC患者带来了希望。传统疗法与新疗法的结合为ICC提供新的诊疗思路。

关键词: 肝内胆管细胞癌, 恶性肿瘤, 诊断, 治疗

Abstract: Intrahepatic cholangiocarcinoma（ICC）is the second most common liver malignancy after hepatocellular carcinoma．It is highly malignant,easy to recur after surgery,and has no typical symptoms in the early stage,and most patients are in the late stage when diagnosed．Diagnosis relies on enhanced CT,MRI and laboratory tests．Hepatectomy is the preferred treatment for intrahepatic cholangiocarcinoma．Complete resection with negative margin and adequate residual liver preservation are important factors affecting the prognosis of the operation．Lymph node dissection and adjuvant chemotherapy with capecitabine have been shown to be beneficial for patients．The rapid development of new therapies such as local therapy,molecular targeted therapy and immunotherapy has brought hope to patients with advanced intrahepatic cholangiocarcinoma．The combination of traditional therapy and new therapy provide a new idea for diagnosis and treatment of intrahepatic cholangiocarcinoma．

Key words: intrahepatic cholangiocarcinoma, carcinoma, diagnosis, treatment

英嵩崧, 高志岩. 肝内胆管细胞癌诊治进展[J]. 广州医药, 2023, 54(6): 100-105.

YING Songsong, GAO Zhiyan. Advances in diagnosis and treatment of intrahepatic cholangiocarcinoma[J]. Guangzhou Medical Journal, 2023, 54(6): 100-105.

参考文献

[1] FLORIO A A,FERLAY J,ZNAOR A,et al.Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012[J].Cancer,2020,126(11):2666-2678.
[2] GAO Z,WANG J,SHEN S,et al.The impact of preoperative biliary drainage on postoperative outcomes in patients with malignant obstructive jaundice:A retrospective analysis of 290 consecutive cases at a single medical center[J]. World J Surg Oncol,2022,20(1):7.
[3] CLEMENTS O,ELIAHOO J,KIM J U,et al.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma:A systematic review and meta-analysis[J].J Hepatol,2020,72(1):95-103.
[4] JIA X,LU S,ZENG Z,et al.Characterization of gut microbiota,bile acid metabolism,and cytokines in intrahepatic cholangiocarcinoma[J].Hepatology,2020,71(3):893-906.
[5] LI Q,CHE F,WEI Y,et al.Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma:from diagnosis and prognosis to treatment response[J].Expert Rev Gastroenterol Hepatol,2021,15(11):1267-1279.
[6] LIU G J,WANG W,LU M D,et al.Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma.Liver Cancer.2015 Dec;4(4):241-252.
[7] FIZ F,MASCI C,COSTA G,et al.PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival[J].Eur J Nucl Med Mol Imaging,2022,49(10):3387-3400.
[8] GUNIGANTI P,KIERANS A S.PET/MRI of the hepatobiliary system:review of techniques and applications[J].Clin Imaging,2021(71):160-169.
[9] ZHANG Y,ZHANG Y,ZHU J,et al.Clinical application of indocyanine green fluorescence imaging in laparoscopic lymph node dissection for intrahepatic cholangiocarcinoma:A pilot study(with video)[J].Surgery,2022,171(6):1589-1595.
[10] ZHANG X F,XUE F,HE J,et al.Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma[J].HPB(Oxford),2021,23(9):1456-1466.
[11] WANG L J,YAN X L,LI J,et al.Indocyanine green clearance test for the preoperative assessment of chemotherapy-related hepatic injury in patients with colorectal liver metastasis[J].Cancer Manag Res,2020(12):3237-3245.
[12] SI A,LI J,YANG Z,et al.Impact of anatomical versus non-anatomical liver resection on short- and long-term outcomes for patients with intrahepatic cholangiocarcinoma[J].Ann Surg Oncol,2019,26(6):1841-1850.
[13] WANG W Q,LI J,LIANG B Y,et al.Anatomical liver resection improves surgical outcomes for combined hepatocellular-cholangiocarcinoma:A propensity score matched study[J]. Front Oncol,2022(12):980736.
[14] GUERRINI G P, ESPOSITO G, TARANTINO G, et al.Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma:the first meta-analysis[J].Langenbecks Arch Surg,2020,405(3):265-275.
[15] REGMI P,HU H J,PAUDYAL P,et al.Is laparoscopic liver resection safe for intrahepatic cholangiocarcinoma?A meta-analysis[J].Eur J Surg Oncol,2021,47(5):979-989.
[16] KANG C M,SUH K S,YI N J,et al.Should lymph nodes be retrieved in patients with intrahepatic cholangiocarcinoma?A collaborative Korea-Japan study[J].Cancers(Basel),2021,13(3):445.
[17] BENSON A B,D’ANGELICA M I,ABBOTT D E,et al.Guidelines Insights:Hepatobiliary Cancers,Version 2.2019[J].J Natl Compr Canc Netw,2019,17(4):302-310.
[18] KITANO Y,YAMASHITA Y I,NAKAGAWA S,et al.Effectiveness of surgery for recurrent cholangiocarcinoma:A single center experience and brief literature review[J].Am J Surg,2020,219(1):175-180.
[19] SAPISOCHIN G,JAVLE M,LERUT J,et al.Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma:Working Group Report From the ILTS Transplant Oncology Consensus Conference[J].Transplantation,2020,104(6):1125-1130.
[20] LUNSFORD K E,JAVLE M,HEYNE K,et al.Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy:A prospective case-series[J].Lancet Gastroenterol Hepatol,2018,3(5):337-348.
[21] ITO T,BUTLER J R,NOGUCHI D,et al.A 3-decade,single-center experience of liver transplantation for cholangiocarcinoma:Impact of era,tumor size,location,and neoadjuvant therapy[J].Liver Transpl,2022,28(3):386-396.
[22] BUETTNER S,KOERKAMP B G,EJAZ A,et al.The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients-A multi-institutional analysis[J].J Surg Oncol,2017,115(3):312-318.
[23] LAMARCA A,PALMER D H,WASAN H S,et al.Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer(ABC-06):a phase 3,open-label,randomised,controlled trial[J].Lancet Oncol,2021,22(5):690-701.
[24] MORIZANE C,OKUSAKA T,MIZUSAWA J,et al.Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer:the FUGA-BT(JCOG1113)randomized phase III clinical trial[J].Ann Oncol,2019,30(12):1950-1958.
[25] LUVIRA V,SATITKARNMANEE E,PUGKHEM A,et al.Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma[J]. Cochrane Database Syst Rev,2021,9(9):CD012814.
[26] LI Q,CHEN C,SU J,et al.Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection:a multi-institutional study[J]. BMC Cancer,2022,22(1):329.
[27] GIORGIO A,CALISTI G,de STEFANO G,et al.Radiofrequency ablation for intrahepatic cholangiocarcinoma:retrospective analysis of a single centre experience[J].Anticancer Res,2011,31(12):4575-4580.
[28] BRANDI G,RIZZO A,DALL’OLIO F G,et al.Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma:a retrospective single-center experience[J].Int J Hyperthermia,2020,37(1):479-485.
[29] LV T R,HU H J,LIU F,et al.The effect of trans arterial chemoembolization in the management of intrahepatic cholangiocarcinoma.A systematic review and meta-analysis[J]. Eur J Surg Oncol,2022,48(5):956-966.
[30] CERCEK A,BOERNER T,TAN B R,et al.Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma:A phase 2 clinical trial[J].JAMA Oncol,2020,6(1):60-67.
[31] LAMARCA A,BARRIUSO J,MCNAMARA M G,et al.Molecular targeted therapies:Ready for “prime time”in biliary tract cancer[J].J Hepatol,2020,73(1):170-185.
[32] ABOU-ALFA G K,MACARULLA T,JAVLE M M,et al.Ivosidenib in IDH1-mutant,chemotherapy-refractory cholangiocarcinoma(ClarIDHy):a multicentre,randomised,double-blind,placebo-controlled,phase 3 study[J].Lancet Oncol,2020,21(6):796-807.
[33] KIM R D,CHUNG V,ALESE O B,et al.A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J].JAMA Oncol,2020,6(6):888-894.